

Karolinska Development AGM 2026: Information on candidates nominated for election or re-election to the board

Re-election

Ben Toogood

Board member since 2021. Chairman between 2024-2026.

Born 1976. Bachelor of Pharmacy from Rhodes University. MSc. from University of Witwatersrand and Executive MBA from University of Cambridge.

Other appointments: CEO, invoX Pharma Limited and Independent Board Member Jamjoom Pharma.

Previous assignments: Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories) and Regulatory Affairs Merck Generics (Mylan).

Independent in relation to the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in KDventures 215,477 shares.

Re-election

Anna Lefevre Skjöldebrand

Board member since 2021.

Born 1969. Master of Laws from Uppsala University.

Other appointments: CEO Swedish Medtech Service AB. Current board assignments include Sweden Medtech4Health AB (chairwoman), Swecare and COCIR.

Previous assignment: Head of Legal Swedish Medtech Service AB, Lawyer Delphi & Co, Lawyer GLS Legal, Legal Counsel Ernst & Young Law, Legal Counsel Front Capital Systems AB. Previous board assignments include Dedicare AB, Danderyds Sjukhus AB, Södertälje Sjukhus Aktiebolag, Södersjukhuset Aktiebolag, E-hälsomyndigheten, SIS AB, Medtech Europe and St Eriks ögonsjukhus. She has also been a member of the board of the Board for Public Procurement.

Independent in relation to the company, its executive management and the company's major shareholders.

No holdings in KDventures.

New election

Anders Hallberg

Born: 1973. Master's degree in Economics and Bachelor's degree in Business Administration from Lund University.

Other appointments: Chairman of the Board of Medivir AB and board member of Hallberg Management AB.

Previous assignments: Founder of HealthInvest Partners AB. Analyst and portfolio manager in the healthcare sector at Carnegie Investment Bank AB/Carnegie Asset Management AB.

Independent in relation to the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in KDventures 92,800,000 shares.

New election

Anders Bladh

Born: 1958. Master's degree in International Business Administration from the University of Uppsala.

Other appointments: Chairman of the Board of Intervalor AB, Rimturs AB and Ribbskottet AB and board member of Xspray Pharma AB and Umecrine Cognition AB.

Previous assignments: Senior Vice President of Handelsbanken International and Corporate Finance departments, CEO of two real estate companies based in Holland and board member of Erik Penser Funds, Medirox AB and Distit AB.

Founder and CEO of Intervalor AB.

Independent in relation to the company, its executive management and to the company's major shareholders.

Holdings in KDventures 1,000,000 shares.

New election

Angelica Loskog

Born: 1973. PhD in Clinical Immunology from Uppsala University.

Other appointments: CEO and board member of Lokon Pharma AB, scientific advisor to the investment company Nexttobe AB, Chairman of the Board of Repos Pharma AB and board member of Medivir AB.

Previous assignments: Chairman of the Board of Vivolux AB and Board member in Chemilia AB, Bioimics AB and Hansa Biopharma AB.

Independent in relation to the company, its executive management and to the company's major shareholders.

No holdings in KDventures.